We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Discovery Laboratories has initiated two Phase II clinical trials utilizing
its Surfactant Replacement Therapy (SRT) to address respiratory disorders that
are prevalent in premature infants in the neonatal intensive care unit.
Inhibitex has announced that enrollment in its ongoing Phase III clinical trial
of Veronate for the prevention of hospital-associated infections in very low
birth weight infants has outpaced the company's initial expectations and that
it has enrolled 684, or more than one-third, of the 2,000 patients it intends
to enroll in the trial.
Dutch biotechnology company Crucell N.V. has been granted a patent by the European
Patent Office specifically relating to the use of its proprietary PER.C6 technology
for the production of vaccines.
Savient Pharmaceuticals has submitted a new drug application (NDA) to the FDA
for Soltamox (tamoxifen oral liquid solution) for the treatment of hormonally
sensitive breast cancer.
ViroPharma has announced that its partner in the development of antiviral compounds
targeting hepatitis C (HCV), Wyeth Pharmaceuticals, a division of Wyeth has
submitted an investigational new drug (IND) application to the FDA to evaluate
ViroPharma's compound HCV-796, a novel polymerase inhibitor, as a potential
new product to treat hepatitis C.
CytRx has announced the publication scientific data showing that its oral
drug candidate, iroxanadine, may help to reduce damage to blood vessels that
occurs when blood flow is restricted and then restored, such as during and
immediately after heart attack and stroke.
People with more copies of a gene that helps to fight HIV are less likely
to become infected with the virus or to develop AIDS than those of the same
geographical ancestry, such as European Americans, who have fewer copies of
the gene, according to a study funded by the National Institute of Allergy
and Infectious Diseases (NIAID), part of NIH.
Sirna Therapeutics has announced that early preclinical research has shown
promising results for the application of RNA interference (RNAi) technology
in the treatment of diabetes.
Enzon Pharmaceuticals has announced the first patient has been dosed in a clinical
trial for ATG-Fresenius S for the prevention of acute organ rejection in patients
receiving lung transplantation.